Dr. Paul Donlin-Asp of the University of Edinburgh to dissect the molecular functions and regulation of local SYNGAP1 protein synthesis with support from CURE SYNGAP1 (fka SynGAP Research Fund)

$130,000 Grant Awarded to Explore Therapeutic Approaches for SYNGAP1-Related Disorders (SRD)

2026-02-09

(Press-News.org) Mill Valley, CA – February 3, 2026 – CURE SYNGAP1 (fka SynGAP Research Fund), a 501(c)(3) organization, announces a $130,000 grant to Dr. Paul Donlin-Asp, PhD, of the Simons Initiative for the Developing Brain (SIDB) at The University of Edinburgh. The grant supports his work in investigating the molecular functions and regulation of local SYNGAP1 protein synthesis, with the goal of advancing therapies for SYNGAP1-Related Disorders (SRD).

Why We Supported This Project Dr. Donlin-Asp’s research focuses on a critical aspect of SRD: the production of SYNGAP1 protein at

synapses, which plays a key role in regulating synaptic strength and plasticity—both essential for learning and memory. Disruptions in SYNGAP1 protein levels lead to the cognitive and developmental challenges observed in individuals with SRD.

This project seeks to map the mechanisms that control the regulation of SYNGAP1 protein in neurons, including the synthesis, location and duration of SYNGAP1 protein. By understanding these molecular processes, Dr. Donlin-Asp aims to identify specific therapeutic targets that could increase SYNGAP1 protein production from existing mRNA, potentially boosting protein levels in affected individuals. This research could lay the foundation for therapeutic strategies aimed at mitigating the symptoms of SRD by restoring proper synaptic function.

While this project focuses on uncovering the fundamental mechanisms that govern SYNGAP1 protein synthesis, its long-term potential is clear: to provide a pathway for developing targeted therapies that address SYNGAP1 protein deficiencies at their source. In doing so, this research brings us closer to CURE SYNGAP1’s ultimate goal—finding effective treatments, and eventually, a cure for SYNGAP1-Related Disorders.

Building on Groundbreaking SYNGAP1 Research Dr. Paul Donlin-Asp is a prominent researcher at the Simons Initiative for the Developing Brain at the University of Edinburgh. His prior work has explored the regulation of protein synthesis in neurons, with a particular focus on SynGAP and its critical role in synaptic function. Similar work funded by CURE SYNGAP1 has also aimed to dissect the complex mechanisms underlying SRD, positioning this project as a continuation of CURE SYNGAP1’s commitment to supporting groundbreaking research in this field.

This project is the latest effort in CURE SYNGAP1’s mission to fund cutting-edge research, building on past initiatives that have provided valuable insights into the role of SYNGAP1 in neurodevelopmental disorders.

Perspectives from the CURE SYNGAP1 Community and Collaborators Lindsay Wieczorek, PhD, CURE SYNGAP1 Board member and former Scientific Director, says, “Understanding the mechanisms behind SYNGAP1 protein synthesis and regulation in the brain is essential for unlocking potential therapies for SYNGAP1-Related Disorders. Dr. Donlin-Asp’s research explores how localized protein production at neural connections supports memory and learning by fine-tuning brain connectivity. By unraveling the molecular processes governing SYNGAP1 levels, this work could be used to develop novel strategies that restore normal cognitive function, offering hope for transformative treatments in neurodevelopmental disorders.”

Kathryn Helde, Chief Scientific Officer, is excited to see the work that comes from this project. “Dr. Donlin-Asp has a fantastic track record of showing patient-relevant findings that give insights to disease mechanisms. His work is collaborative and aims to understand questions that affect patient health.”

“The University of Edinburgh continues to be a centre of excellence in the UK, and the work that they do continues to offer hope to the SYNGAP1 community in the UK and beyond,” shared Julie Pender, Chair of CURE SYNGAP1 UK. “CURE SYNGAP1’s support of this research makes a big difference to those of us navigating SYNGAP1 here in the UK, knowing that our fundraising efforts will help bring a more positive future for our Syngapians.”

“This funding from [CURE SYNGAP1] is pivotal in advancing our understanding of how SYNGAP1 protein synthesis is regulated at the molecular level,” says Dr. Donlin-Asp. “By unlocking these intricate mechanisms, we aim to uncover novel strategies to enhance SYNGAP1 protein production—laying the groundwork for potential therapeutic interventions that could transform the lives of individuals affected by SynGAP-related intellectual disability.”

Family Donations Make Progress Possible “SYNGAP1 families and our dedicated donors aren’t just waiting for progress—they’re making it happen,” said CURE SYNGAP1 President and Chief Operating Officer, Virginie McNamar. “Their commitment to fundraising and supporting our mission allows us to invest in critical research that drives real change. This grant is a direct result of their efforts, and we are deeply grateful for their support in pushing SYNGAP1 science forward.”

About the Simons Initiative for the Developing Brain (SIDB) SIDB is a research center based at the University of Edinburgh, bringing together around 40 principal investigators across six research sites to understand the fundamental basis of monogenic neurodevelopmental disorders characterized by autism, intellectual disability and epilepsy. SIDB was founded in 2017, following a generous donation from the Simons Foundation Autism Research Initiative (SFARI).

SIDB partners with the Patrick Wild Centre, founded in 2010, with the mission of understanding the neurological basis of and developing new therapeutic intervention for monogenic forms of autism, and intellectual disabilities. A key research and clinical focus of both SIDB and the PWC is SYNGAP1 haploinsufficiency.

About SYNGAP1-Related Disorders (SRD) SYNGAP1-Related Disorders (ICD-10 F78.A1) are a rare genetic disorder caused by variants on the SYNGAP1 gene that reduce SYNGAP1 protein levels. CURE SYNGAP1 has identified over 1,707 SRD patients to date, and the number grows weekly. This protein acts as a regulator in the synapses (where neurons communicate with each other). When SYNGAP1 protein levels are too low, we see an increase in excitability in the synapses making it difficult for neurons to communicate effectively. This leads to many neurological issues seen in SRD patients.

Symptoms of SRD include primarily neurological issues including autism spectrum disorder (ASD), intellectual disability, epilepsy, hypotonia (low muscle tone), gross and fine motor delays, global developmental delay, and visual abnormalities such as strabismus (crossed eyes) as well as gastrointestinal challenges and disordered sleep.

About CURE SYNGAP1’s Seven Scientific Programs CURE SYNGAP1 has seven scientific programs. These programs reflect their urgency to develop disease modifying treatments. These include the following:

BTS – Basic and Translational Science Purpose – Drug Repurposing SMART – SYNGAP1 Missense Analysis, Research & Therapeutics SBOM – SYNGAP1 Biomarkers & Endpoints Facilitate – Develop and Share Patient-relevant Research Tools and Reagents SRDC – SYNGAP1-Related Disorders Characterization ProMMiS: Prospective Multidisciplinary, Multisite Study for Clinical Excellence – Natural History Study at Multidisciplinary Clinics This grant falls into the BTS program. Basic Science reveals what goes wrong in tissues and cells when a SYNGAP1 gene is broken. Translational Science is the designing and testing of different types of medicines for SRD. CURE SYNGAP1 has funded over $3M in BTS grants.

About CURE SYNGAP1 CURE SYNGAP1 improves the quality of life for SYNGAP1 patients through the research and development of treatments, therapies, and support systems.

CURE SYNGAP1 was founded in the US in 2018 as a 501(c)(3) US public charity. There are sister organizations founded by local families in the UK in 2020, Europe (the Netherlands) in 2022, as well as both Australia & Latin America (Colombia) in 2023. Completely family-led, CURE SYNGAP1 is a leading funder of SYNGAP1 research having committed over $8 million in grants as of December 31, 2025.

CURE SYNGAP1’s grant program awards pilot, one-year and two-year grants to researchers and clinicians studying SYNGAP1. Their mission is to accelerate the availability of safe and effective treatments that meaningfully modify SRD to reduce suffering for patients and their families. Current funding priorities include essential milestones for clinical trial readiness. You can learn more about CURE SYNGAP1 and their accomplishments by reading their most recent Impact Report.

For more on CURE SYNGAP1, visit curesyngap1.org or follow @cureSYNGAP1 on LinkedIn, YouTube, Instagram, Facebook, TikTok, and X.

CURE SYNGAP1 (fka SynGAP Research Fund) is a member of FasterCures, COMBINEDBrain, Global Genes Foundation Alliance, Everylife Foundation Community Congress, Epilepsies Action Network, Personalized Medicine Coalition, Rare Epilepsy Network, Epilepsy Leadership Council, Alliance for Genetic Etiologies in Neurodevelopmental Disorders and Autism (AGENDA), California Action Link for Rare Diseases, American Brain Coalition, Genetic Alliance UK, Rare Disease UK, Syndromes Without a Name (SWAN UK), Jumpstart Program, Patient Worthy, Autism Brain Net, Innovation and Value Initiative, Rare Disease Diversity Coalition, Cambridge Rare Disease Network, Breaking Down Barriers, Rare-X, Mencap, IndoUSRare, The World Orphan Drug Congress, and Research America.

END

ELSE PRESS RELEASES FROM THIS DATE:

Seeing the whole from a part: Revealing hidden turbulent structures from limited observations and equations

2026-02-09

The irregular, swirling motion of fluids we call turbulence can be found everywhere, from stirring in a teacup to currents in the planetary atmosphere. This phenomenon is governed by the Navier–Stokes equations—a set of mathematical equations that describe how fluids move. Despite being known for nearly two centuries, these equations still pose major challenges when it comes to making predictions. Turbulent flows are inherently chaotic, and tiny uncertainties can grow quickly over time. In real-world situations, scientists can only observe part of a turbulent flow, usually its largest and slowest ...

Unveiling polymeric interactions critical for future drug nanocarriers

2026-02-09

Polymer micelles are tiny, self-assembled particles that are revolutionizing the landscape of drug delivery and nanomedicine. They form when polymer chains containing both hydrophilic and hydrophobic segments organize into nanoscale spheres in liquid solutions; these structures can trap and hold drugs that are otherwise difficult to dissolve. Poloxamer 407 (P407), a widely studied micelle-forming polymer, is particularly useful because it changes from a liquid into a soft gel as it warms, becoming most stable near body temperature. This temperature-dependent gelling behavior ...

New resource supports trauma survivors, health professionals

2026-02-09

A new digital resource co-created by University of Victoria (UVic) researchers and trauma survivors will streamline access to resources and tools for clinicians who support people with complex post-traumatic stress at Island Health in B.C. and other jurisdictions. To enhance trauma-informed health care for people experiencing complex post-traumatic stress disorder (C-PTSD), an online site has been built to provide the information and tools professionals need to respond to emerging patient care needs. Using multimedia including videos, handouts and quizzes, the tool provides information on C-PTSD, how it affects people mentally ...

Evidence of a subsurface lava tube on Venus

2026-02-09

Volcanic activity is not unique to Earth: traces of volcanic activity, such as lava tubes, have been found on Mars and the Moon. Now, the University of Trento has demonstrated the existence of an empty lava tube even in the depths of Venus, a planet whose surface and geology have been largely shaped by volcanic processes. The cave was identified through radar data analysis as part of a project funded by the Italian Space Agency. The discovery was published by Nature Communications. "Our knowledge of Venus is still limited, and until now we have never had the opportunity to directly observe processes occurring beneath the surface of Earth’s twin planet. ...

New trial aims to transform how we track our daily diet

2026-02-09

Scientists are recruiting adults from across the UK to take part in a groundbreaking trial to accurately track what they eat and drink in their daily lives. The findings of their research could pave the way for better public health strategies to tackle diseases linked to poor diets such as type 2 diabetes, heart disease and some cancers. Currently diets are measured by people completing complex and time-consuming nutrition surveys themselves and trying to remember exactly what they have eaten, but this can lead ...

People are more helpful when in poor environments

2026-02-09

People are more likely to act helpfully in situations where there are poorer choices to give to others, according to a new study that tested willingness to help others in different contexts. The paper, published in Nature Communications today (Monday 9 February), is the culmination of three studies involving more than 500 participants and led by academics from the University of Birmingham. The team, which also included academics from Oxford University and the University of East Anglia, found that when people were in a poor environment they were surprisingly more likely to help compared to the richer environment. Dr ...

How big can a planet be? With very large gas giants, it can be hard to tell

2026-02-09

Gas giants are large planets mostly composed of helium and/or hydrogen. Although these planets have dense cores, they don’t have hard surfaces. Jupiter and Saturn are the gas giants in our solar system, but there are many other gas giant exoplanets in our galaxy and some are many times larger than Jupiter. The largest gas giants blur the line between planets and brown dwarfs — those substellar objects, sometimes called “failed stars” because they do not fuse hydrogen. How do these gas giants form? Was it through core accretion, where solid cores gradually ...

New method measures energy dissipation in the smallest devices

2026-02-09

In order to build the computers and devices of tomorrow, we have to understand how they use energy today. That’s harder than it sounds. Memory storage, information processing, and energy use in these technologies involve constant energy flow – systems never settle into thermodynamic balance. To complicate things further, one of the most precise ways to study these processes starts at the smallest scale: the quantum domain. New Stanford research published Feb. 9 in Nature Physics combines theory, experimentation, and machine learning ...

More than 1,000 institutions worldwide now partner with MDPI on open access

2026-02-09

MDPI, the Open Access (OA) publisher, today announced more than 1,000 partners have joined its Institutional Open Access Program (IOAP), a significant milestone for the organization. The agreements span 59 countries, covering North and South America, Europe, Asia, Africa, and Oceania. Last year alone, more than 150 new libraries and academic institutions joined MDPI’s IOAP. The expansion of an existing consortium deal in Sweden added a further 75 partners to the publisher’s portfolio in January 2026, ...

Chronic alcohol use reshapes gene expression in key human brain regions linked to relapse vulnerability and neural damage

2026-02-09

Chronic alcohol consumption profoundly alters gene expression in key brain regions involved in reward, impulse control, and decision-making, according to a study led by researchers at the Institute for Neurosciences, a joint center of Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC). Published in the journal Addiction, the work provides new insight into the biological basis of alcohol addiction and points toward potential therapeutic targets. “Alcohol use disorder is one of the leading causes of disease and death worldwide, yet despite its enormous social and health impact, available treatment options ...

LAST 30 PRESS RELEASES:

Cognitive speed training linked to lower dementia incidence up to 20 years later

Businesses can either lead transformative change or risk extinction: IPBES

Opening a new window on the brainstem, AI algorithm enables tracking of its vital white matter pathways